Clinical trial
Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
NCT00365222 · H. Lee Moffitt Cancer Center and Research Institute, Other · Terminated
Key facts
| NCT number | NCT00365222 |
|---|---|
| Title | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma |
| Official title | Phase II Study of Dose Intensive Temozolomide in Elderly Adults With Newly Diagnosed Glioblastoma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | Schering-Plough Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma, Gliosarcoma |
| Intervention type | Drug |
| Interventions | Temozolomide |
| Enrollment | 1 |
| Start date | Jul 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Aug 17, 2006 |
| Last update posted | Jan 22, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: